TAMIFLU ORAL SUSPENSION POWDER FOR SUSPENSION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE)

Pieejams no:

HOFFMANN-LA ROCHE LIMITED

ATĶ kods:

J05AH02

SNN (starptautisko nepatentēto nosaukumu):

OSELTAMIVIR

Deva:

12MG

Zāļu forma:

POWDER FOR SUSPENSION

Kompozīcija:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 12MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

75ML

Receptes veids:

Prescription

Ārstniecības joma:

NEURAMINIDASE INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0139501002; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2013-12-12

Produkta apraksts

_ _
_ _
_Page 1 of 53_
PRODUCT MONOGRAPH
PR
TAMIFLU
®
oseltamivir capsule
30 mg, 45 mg and 75 mg oseltamivir (as oseltamivir phosphate)
oseltamivir powder for oral suspension
6 mg/mL and 12 mg/mL oseltamivir (as oseltamivir phosphate) when
reconstituted
Antiviral Agent
Hoffmann-La Roche Limited
2455 Meadowpine Boulevard
Mississauga, Ontario
L5N 6L7
Date of Revision:
June 12, 2012
www.rochecanada.com
SUBMISSION CONTROL NO: 155227
Manufactured under license from Gilead Sciences Inc.
®
Trade-Mark of F. Hoffmann-La Roche AG, used under license
©
Copyright 1999-2012 by Hoffmann-La Roche Limited
_ _
_ _
_Page 2 of 53_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
..................................................................